|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||50.26 - 50.82|
|52-week range||50.26 - 50.82|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||N/A|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||38.30|
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.